Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.58 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.58 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.57 |
| ▸ | KDM1A | O60341 | 4/20 | 0.55 |
| ▸ | MAOB | P27338 | 4/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527236 | 1.00 | CYP4F2 (0.58) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL31728652 | 1.00 | CYP4F2 (0.58) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL527235 | 1.00 | CYP4F2 (0.58) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL18923951 | 0.89 | KCNH2 (0.58) | CYP4F2CYP4A11KDM1AMAOBMAOA | |
| SCHEMBL3749297 | 0.88 | FFAR1 (0.71) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL13043524 | 0.88 | FFAR1 (0.71) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL19609293 | 0.87 | CYP4F2 (0.57) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL15687569 | 0.87 | MAOB (0.52) | CYP4F2CYP4A11FFAR1KDM1AMAOB | |
| SCHEMBL1100308 | 0.87 | FFAR1 (0.69) | CYP4F2CYP4A11FFAR1MAOA | |
| SCHEMBL2774821 | 0.86 | MAOB (0.54) | KDM1AMAOBMAOARAB9ANR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3495349-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2023-06-28 | — | — | EP | disclosed |
| EP-3736265-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | Oryzon Genomics, S.A. (ES) | 2020-11-11 | — | — | EP | disclosed |
| EP-2768805-B1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2020-03-25 | — | — | EP | disclosed |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2019-06-25 | — | — | US | disclosed |
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2019-03-19 | — | — | US | disclosed |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | ORYZON GENOMICS SA (ES) | 2018-05-10 | — | — | US | disclosed |
| US-9944601-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS, S.A. (ES) | 2018-04-17 | — | — | US | disclosed |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | ORYZON GENOMICS SA (ES) | 2018-03-22 | — | — | US | disclosed |
| US-9708309-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | ORYZON GENOMICS, S.A. (ES) | 2017-07-18 | — | — | US | disclosed |
| US-9670136-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | ORYZON GENOMICS S.A. (ES) | 2017-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233178-B2 | Arylcyclopropylamine based demethylase inhibitors of LSD1 and their medical use | KDM6A, KDM1B, KDM1A | CYP4F2 471/4885CYP4A11 470/4885FFAR1 2820/4885 |
| US-20180127406-A1 | ARYLCYCLOPROPYLAMINE BASED DEMETHYLASE INHIBITORS OF LSD1 AND THEIR MEDICAL USE | KDM6A, KDM1B, KDM1A | CYP4F2 471/4885CYP4A11 470/4885FFAR1 2820/4885 |
| US-10329256-B2 | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | CYP4F2 773/4885CYP4A11 1410/4885FFAR1 3080/4885 |
| US-20180079709-A1 | (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | CYP4F2 644/4885CYP4A11 1134/4885FFAR1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.